The invention relates to the technical field of bone
metabolism disease related markers, in particular to application of CASQ1
protein in preparation of bone
metabolism related
disease diagnosis and / or screening products. It is found that when the
muscle function is abnormal or damaged, the content of CASQ1
protein in exosomes secreted by
muscle cells is increased, the exosomes can be transferred to adjacent
bone tissue, the osteogenic differentiation of
bone marrow mesenchymal stem cells is inhibited, and then
bone metabolism disorder is caused. The invention provides a diagnostic kit and a pharmaceutical composition taking CASQ1
protein as a detection target. The diagnostic kit and the pharmaceutical composition are used for early screening and diagnosis of bone metabolic diseases such as myogenic
osteoporosis, fracture healing disorder and bone
dysplasia. By detecting the content change of the CASQ1 protein in tissues or body fluids, quantitative evaluation of
muscle dysfunction related bone
metabolism abnormality can be realized, and a new detection means and a
biological target are provided for
clinical diagnosis and
treatment intervention of related diseases.